Key result
Protocol report: study outlines rationale for erythropoiesis-stimulating agents and platelet aggregation with no results reported.
Why the study?
Erythropoiesis-stimulating agents are widely used to treat renal anemia in chronic renal failure patients, but their effect on platelet aggregation in peritoneal dialysis patients is unclear.
Observational
ESA effects on platelet aggregation in peritoneal dialysis remain inconclusive; leaves open any impact on bleeding risk.
Introduction: Erythropoietin (Epo) is a hormone that is synthesized in the kidneys and that stimulates the erythropoiesis in the bone marrow. Epo has effects apart from the erythropoiesis. In chronic renal failure (CRF) patients, hemorrhagic diathesis is observed, and Epo production is decreased. Erythropoiesis-stimulating agents (ESAs) are widely used in the treatment of renal anemia in these patients. Our study aimed to investigate the effect of ESA5 use on platelet aggregation in peritoneal dialysis (PD) patients due to CRF.
No takes yet. Share an insight, caveat, or question.
Bakırdöğen et al. (2019) conducted an observational in Chronic renal failure requiring peritoneal dialysis. Erythropoiesis-stimulating agents (ESAs) was evaluated on Platelet aggregation. The abstract only describes the study rationale and aim, and does not report any results regarding the effect of erythropoiesis-stimulating agents on platelet aggregation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: